

1121842

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM D
NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

OMB Num Expires: Estimated response. 04050905
SEC USE ONLY
Prefix Serial
DATE RECEIVED

SEC MAIL RECEIVED DEC 13 2004 WASH. D.C. 202

PROCESSED DEC 15 2004 THOMSON FINANCIAL

Name of Offering () check if this is an amendment and name has changed, and indicate change.)
Common stock and warrants

Filing Under (Check box(es) that apply): () Rule 504 () Rule 505 [X] Rule 506 () Section 4(6) () ULOE

Type of Filing: [X] New Filing () Amendment

A. BASIC IDENTIFICATION DATA

1. Enter the information requested about the issuer

Name of Issuer () check if this is an amendment and name has changed, and indicate change.)
Duska Therapeutics, Inc.

Address of Executive Offices (Number and Street, City, State, Zip Code) Telephone Number (Including Area Code)
Two Bala Plaza, Suite 300, Bala Cynwyd, PA 19004 (610) 660-6690

Address of Principal Business Operations (Number and Street, City, State, Zip Code) Telephone Number (Including Area Code)
(if different from Executive Offices) Same Same

Brief Description of Business
PHARMACEUTICAL RESEARCH AND DEVELOPMENT

Type of Business Organization
[X] corporation () limited partnership, already formed () other (please specify):
() business trust () limited partnership, to be formed

Actual or Estimated Date of Incorporation or Organization: Month Year [X] Actual () Estimated
Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State: [NV]
CN for Canada; FN for other foreign jurisdiction)

GENERAL INSTRUCTIONS

Federal:
Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR230.501 et seq. or 15 U.S.C. 77d(6).
When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering...
Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549
Copies Required: Five (5) copies of this notice must be filed with the SEC...
Information Required: A new filing must contain all information requested.
Filing Fee: There is no federal filing fee.

State:
This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.



A. BASIC IDENTIFICATION DATA

2. Enter the information requested for the following:

- Each promoter of the issuer, if the issuer has been organized within the past five years;
- Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
- Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
- Each general and managing partner of partnership issuers.

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)
Mosk, Manfred

Business or Residence Address (Number and Street, City, State, Zip Code)
Two Bala Plaza, Suite 300, Bala Cynwyd, PA 19004

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)
Nisi, Rudolph

Business or Residence Address (Number and Street, City, State, Zip Code)
Two Bala Plaza, Suite 300, Bala Cynwyd, PA 19004

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)
Kapoor, John

Business or Residence Address (Number and Street, City, State, Zip Code)
Two Bala Plaza, Suite 300, Bala Cynwyd, PA 19004

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)
Pelleg, Amir

Business or Residence Address (Number and Street, City, State, Zip Code)
Two Bala Plaza, Suite 300, Bala Cynwyd, PA 19004

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)
Jane Kinsel

Business or Residence Address (Number and Street, City, State, Zip Code)
Two Bala Plaza, Suite 300, Bala Cynwyd, PA 19004

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)
Hillsberg, Sanford J.

Business or Residence Address (Number and Street, City, State, Zip Code)
1801 Century Park East, Suite 1600, Los Angeles, CA 90067

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)
Benditt, David

Business or Residence Address (Number and Street, City, State, Zip Code)
Two Bala Plaza, Suite 300, Bala Cynwyd, PA 19004

Check Box(es) that Apply: Promoter Beneficial Owner Executive Officer Director General and/or Managing Partner

Full Name (Last name first, if individual)
Sciocchetti, Marie

Business or Residence Address (Number and Street, City, State, Zip Code)
Two Bala Plaza, Suite 300, Bala Cynwyd, PA 19004

B. INFORMATION ABOUT OFFERING

1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering? Yes No
- Answer also in Appendix, Column 2, if filing under ULOE
2. What is the minimum investment that will be accepted from any individual? N/A
3. Does the offering permit joint ownership of a single unit? Yes No
4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.

Full Name (Last name first, if individual)

Business or Residence Address (Number and Street, City, State, Zip Code)

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers

(Check "All States" or check individual States) All States

[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]

Full Name (Last name first, if individual)

Business or Residence Address (Number and Street, City, State, Zip Code)

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers

(Check "All States" or check individual States) All States

[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]

Full Name (Last name first, if individual)

Business or Residence Address (Number and Street, City, State, Zip Code)

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers

(Check "All States" or check individual States) All States

[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.

Type of Security	Aggregate Offering Price	Amount Already Sold
Debt.....	\$ _____	\$ _____
Equity (units of common stock and warrants).....	\$ _____ ***	\$ _____ ***
[X] Common [] Preferred		
Convertible Securities (including warrants) warrants (see above)	\$ _____	\$ _____
Partnership Interests.....	\$ _____	\$ _____
Other (Specify _____)	\$ _____	\$ _____
Total	\$ _____ ***	\$ _____ ***

Answer also in Appendix, Column 3, if filing under ULOE

2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."

	Number Investors	Aggregate Dollar Amount of Purchases
Accredited Investors	76	\$ _____ ***
Non-accredited Investors	_____	\$ _____
Total (for filings under Rule 504 only)	_____	\$ _____

Answer also in Appendix, Column 4, if filing under ULOE

3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities of this offering. Classify securities by type listed in Part C - Question 1.

Type of offering	Type of Security	Dollar Amount Sold
Rule 505	_____	\$ _____
Regulation A	_____	\$ _____
Rule 504	_____	\$ _____
Total	_____	\$ _____

4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.

Transfer Agent's Fees.....	<input type="checkbox"/>	\$ 1,700
Printing and Engraving Costs	<input type="checkbox"/>	\$ 1,000
Legal Fees	<input type="checkbox"/>	\$ 0
Accounting Fees.....	<input type="checkbox"/>	\$ 0
Engineering Fees.....	<input type="checkbox"/>	\$ 0
Sales Commissions (specify finders' fees separately)	<input type="checkbox"/>	\$ 0
Other Expenses (identify: Reimbursement of broker's expenses)	<input type="checkbox"/>	\$ 0
Total	<input type="checkbox"/>	\$ 2,700

***This Form D is being filed in connection with a merger in which the Issuer issued 17,727,801 shares of its common stock to the stockholders of Duska Scientific Co. in exchange for all of the issued and outstanding shares of capital stock of Duska Scientific Co., warrants totaling 8,651,551 shares of Issuer's common stock and stock options totaling 4,915,000 shares of Issuer's common stock in exchange for all of Duska Scientific Co.'s outstanding warrants and options. None of the Duska Scientific Co. stockholders paid any cash for any of the Issuer's securities, and all expenses listed above relate to expenses incurred in connection with the merger by the Issuer.

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

4. b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer." \$ N/A***

5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above.

		Payments to Officers, Directors, & Affiliates		Payments To Others
Salaries and fees.....	<input type="checkbox"/>	\$ _____	[]	\$ _____
Purchase of real estate	[]	\$ _____	[]	\$ _____
Purchase, rental or leasing and installation of machinery and equipment.....	[]	\$ _____	[]	\$ _____
Construction or leasing of plant buildings and facilities.....	[]	\$ _____	[]	\$ _____
Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger).....	[]	\$ _____	[]	\$ _____
Repayment of indebtedness.....	[]	\$ _____	[]	\$ _____
Working capital	[]	\$ _____	[]	\$ _____
Other(specify): _____	[]	\$ _____	[]	\$ _____
_____	[]	\$ _____	[]	\$ _____
Column Totals	<input type="checkbox"/>	\$ _____	<input type="checkbox"/>	\$ _____
Total Payments Listed (column totals added).....		\$ _____	<input type="checkbox"/>	\$ <u>N/A***</u>

D. FEDERAL SIGNATURE

The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

Issuer (Print or Type) Duska Therapeutics, Inc..	Signature <i>A. Pelleg</i>	Date <i>11/29/04</i>
Name of Signer (Print or Type) Amir Pelleg, Ph.D.	Title of Signer (Print or Type) President	

***This Form D is being filed in connection with a merger in which the Issuer issued 17,727,801 shares of its common stock to the stockholders of Duska Scientific Co. in exchange for all of the issued and outstanding shares of capital stock of Duska Scientific Co., warrants totaling 8,651,551 shares and stock options totaling 4,915,000 shares of its common stock. None of the Duska Scientific Co. stockholders paid any cash for any of the Issuer's securities, and all expenses listed above relate to expenses incurred in connection with the merger

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001).

E. STATE SIGNATURE

1. Is any party described in 17 CFR 230.262(c), (d), (e) or (f) presently subject to any of the disqualification provisions of such rule? Yes No
[] [X]

See Appendix, Column 5, for state response.

2. The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239.500) at such times as required by state law.

3. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.

4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform Limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

Issuer (Print or Type) Duska Therapeutics, Inc.	Signature <i>A. Pelleg</i>	Date <i>11/29/04</i>
Name of Signer (Print or Type) Amir Pelleg, Ph.D.	Title of Signer (Print or Type) President	

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

APPENDIX

1 State	2 Intend to sell to non-accredited investors in State (Part B-Item 1)		3 Type of Security and aggregate offering price offered in state (Part C-Item 1)	4 Type of investor and amount purchased in State (Part C-Item 2)				5 Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)	
	Yes	No		Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
AL									
AK									
AZ									
AR									
CA		X	<i>Common stock, options, warrants</i>	30	9,570,125 shares 3,796,559 options & warrants	0	0		X
CO		X	<i>Common stock, warrants</i>	2	49,200 shares 175,250 warrants	0	0		X
CT		X	<i>Common stock, options warrants</i>	2	105,918 shares 444,918 options and warrants	0	0		X
DE									
DC									
FL		X	<i>Common stock, warrants</i>	2	75,000 shares 100,000 warrants	0	0		X
GA		X	<i>Option</i>	1	60,000 option	0	0		X
HI		X	<i>Common stock, warrants</i>	1	89,310 shares 112,110 warrants				
ID		X	<i>Common stock, warrants</i>	1	50,000 shares 100,000 warrants	0	0		X
IL		X	<i>Common stock, warrants</i>	2	1,408,049 shares 4,260,815 options & warrants	0	0		X

APPENDIX

1 State	2 Intend to sell to non-accredited investors in State (Part B-Item 1)		3 Type of Security and aggregate offering price offered in state (Part C-Item 1)	4 Type of investor and amount purchased in State (Part C-Item 2)				5 Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)	
	Yes	No		Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
IN									
IA									
KS									
KY									
LA									
ME									
MD		X	<i>Options</i>	<i>1</i>	<i>120,000 options</i>	<i>0</i>	<i>0</i>		X
MA									
MI									
MN		X	<i>Options</i>	<i>1</i>	<i>105,000 options</i>	<i>0</i>	<i>0</i>		X
MS									
MO									
MT		X	<i>Common stock, warrants</i>	<i>1</i>	<i>50,000 shares 100,000 warrants</i>	<i>0</i>	<i>0</i>		X
NE									
NV		X	<i>Common stock, warrants</i>	<i>1</i>	<i>50,000 shares 50,000 warrants</i>	<i>0</i>	<i>0</i>		X
NH									
NJ		X	<i>Common stock, warrants</i>	<i>2</i>	<i>102,481 shares 174,481 warrants</i>	<i>0</i>	<i>0</i>		X
NM									
NY		X	<i>Common stock, warrants</i>	<i>4</i>	<i>149,200 shares 55,000 warrants</i>	<i>0</i>	<i>0</i>		X
NC									
ND									

APPENDIX

1	2		3	4				5	
	Intend to sell to non-accredited investors in State (Part B-Item 1)			Type of investor and amount purchased in State (Part C-Item 2)				Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)	
State	Yes	No		Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
OH									
OK									
OR		X	<i>Common stock, warrants</i>	1	50,000 shares 50,000 warrants	0	0		X
PA		X	<i>Common stock, options, warrants</i>	5	4,253,118 shares 1,863,918 options & warrants	0	0		X
RI									
SC									
SD									
TN									
TX									
UT									
VT									
VA									
WA		X	<i>Common stock, warrants</i>	1	85,000 shares 85,000 warrants	0	0		X
WV									
WI		X	<i>Common stock, warrants</i>	1	25,000 shares 25,000 warrants	0	0		X
WY									

Foreign: Plus 17 foreign investors totaling 1,615,400 shares common stock and 1,938,500 option and warrant shares